居家健康促进干预对英国轻度衰弱老年人的临床与成本效果:多中心平行组随机对照试验
本研究在英国多中心纳入388名65岁以上、临床衰弱量表评分为5的社区轻度衰弱老年人,随机分为居家行为改变健康促进干预(HomeHealth)组和常规治疗组。
要点
- HomeHealth未改善12个月独立功能(Barthel指数)。
- 干预组增量成本点估计为负、QALY点估计为正,成本效果概率高。
- 干预安全,严重不良事件数低于常规治疗组且均与干预无关。
核心结论
- HomeHealth是安全的干预措施,具有高概率的成本效果,其驱动因素为非计划住院减少。
- 应考虑将HomeHealth作为轻度衰弱老年人的健康促进干预。
研究设计与样本
- 英国多中心、个体随机、平行组随机对照试验,1:1随机分配至HomeHealth或常规治疗。
- 共纳入388名社区居住、65岁及以上、临床衰弱量表评分为5、预期寿命超过6个月且有能力同意的老年人。
- HomeHealth由志愿部门在家提供,为期6个月共6次 sessions,为多维度健康促进干预。
- 主要结局为12个月时改良Barthel指数评估的独立功能,采用线性混合模型意向性分析。
主要发现
- HomeHealth组严重不良事件55例,常规治疗组85例,均与干预无关。
临床怎么用
- 对于社区轻度衰弱老年人,可考虑提供由志愿部门实施的居家多维度健康促进干预。
- 该干预虽未改善独立功能评分,但可能通过减少非计划住院而具有成本效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Health promotion for people with mild frailty has the potential to improve health outcomes, but such services are scarce in practice. We developed a personalised, home-based, behaviour change, health promotion intervention (HomeHealth) and assessed its clinical effectiveness and cost-effectiveness in maintaining independent functioning in activities of daily living in older adults with mild frailty. METHODS: This trial was an individual, multicentre, parallel-group, randomised controlled trial done in England. Participants were mainly recruited from general practices in three different areas of England (the London north Thames region, east and north Hertfordshire, and west Yorkshire). Participants were individuals residing in the community who were registered with a general practice, 65 years and older with mild frailty (scoring 5 on the CFS), with a life expectancy of more than 6 months, and with capacity to consent to participate. We excluded adults residing in nursing or care homes, those with moderate-to-severe frailty or with no frailty, those receiving palliative care, and those already case managed (eg, receiving a similar ongoing intervention from the voluntary sector or community service). Eligible participants were randomly assigned 1:1 to either the HomeHealth intervention or to treatment as usual. HomeHealth is a multidomain health promotion intervention delivered by the voluntary sector at home in six sessions over 6 months. The primary outcome was independent functioning (assessed using the modified Barthel Index [BI]) at 12 months. Outcome assessments were masked and were analysed by intention to treat using linear mixed models. Incremental costs and quality-adjusted life-years (QALYs) were calculated using seemingly unrelated regression and bootstrapping. The trial is registered on the ISRCTN registry (ISRCTN54268283). FINDINGS: We recruited 388 participants between Jan 8, 2021 and July 2, 2022 (mean age 81 years, SD 6·5; 249 (64%) of 388 were women and 139 (36%) were men). 195 participants were randomly assigned to HomeHealth and 193 to treatment as usual. Median follow-up was 363 days (IQR 356-370) in the HomeHealth group and 362 days (IQR 355-373) in the treatment-as-usual group. HomeHealth did not improve BI scores at 12 months (mean difference 0·250, 95% CI -0·932 to 1·432). HomeHealth was superior to treatment as usual with a negative point estimate for incremental costs (-£796; 95% CI -2016 to 424) and positive point estimate for incremental QALYs (0·009, -0·021 to 0·039). There were 55 serious adverse events in the HomeHealth group and 85 in the treatment-as-usual group; none were intervention related. INTERPRETATION: HomeHealth is a safe intervention with a high probability of cost-effectiveness, driven by a reduction in unplanned hospital admissions. HomeHealth should be considered as a health promotion intervention for older people with mild frailty. FUNDING: National Institute for Health Research Health Technology Assessment.
引用
- Walters K, Frost R, Avgerinou C, et al. Clinical and cost-effectiveness of a home-based health promotion intervention for older people with mild frailty in England: a multicentre, parallel-group, randomised controlled trial. Lancet Healthy Longev. 2025. PMID: 40015296. doi:10.1016/j.lanhl.2024.100670
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。